Background: First-degree relatives (FDRs) of chronic kidney disease (CKD) patients have a high prevalence of CKD and its risk factors. We evaluated adult FDRs of end-stage renal disease (ESRD) patients for the prevalence of CKD and its risk factors. Methods: Adult FDRs of ESRD patients were screened. Patients <18 years of age with CKD due to polycystic kidney disease, diabetic nephropathy and urological disease were excluded. Age, sex, hypertension, weight, blood pressure, urine analysis, fasting blood glucose, serum creatinine and cholesterol were done. Results: 606 FDRs of 145 index patients were screened; mean age was 39.8 years and 53.3% were male, 26 obese and 122 overweight. 29.7% had hypertension and 3.6% diabetes mellitus. Screening identified new cases of hypertension (21.5%), diabetes mellitus (2.0%), impaired fasting glucose (22.4%) and hypercholesterolemia (18.8%). 5.9% had proteinuria (≧1+). 61.2% of FDRs had eGFR in stage 1, 34.7% in stage 2, 3.6% in stage 3, and 0.5% in stage 4–5. 8.6% had CKD (88.5% were unaware). On multivariate analysis, older age, female sex, proteinuria and uncontrolled blood pressure had a significant association with eGFR <60 ml/min/1.73 m2. Conclusion: In India, CKD and its risk factors show a familial clustering, and screening of FDRs of ESRD patients will be a viable option for a CKD preventive program.

1.
Perico N, Codreanu I, Schieppati A, Remuzzi G: The scientific care for prevention: an overview. Kidney Int 2005;67(suppl 94):S8–S13.
2.
Grassmann A, Gioberge S, Moeller S, Brown G: ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587–2593.
3.
Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12.
4.
Centre for Disease Control and Prevention (CDC): Prevalence of chronic kidney disease and associated risk factors – United States, 1999–2004. MMWR 2007;56:161–165.
5.
Barsoum RS: Chronic kidney disease in the developing world. N Engl J Med 2006;354:997–999.
6.
Agarwal SK, Srivastava RK: Chronic kidney disease in India: challenges and solutions. Nephron Clin Pract 2009;111:c197–c203.
7.
Agarwal SK, Dash SC, Irshad M, Raju S, Singh R, Pandey RM: Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant 2005;20:1638–1642.
8.
Agarwal SK: Chronic kidney disease and its prevention in India. Kidney Int 2005;98:S41–S45.
9.
Agarwal SK: Prevention of chronic kidney disease in India (editorial). J Int Med Sci Acad 2007;20:291.
10.
Dirk JH, De Zeeuw D, Agarwal SK, et al: Prevention of chronic kidney disease: towards global health equity – the Bellagio 2004 declaration. Kidney Int 2005;98:S1–S6.
11.
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis 2002;39(suppl 1): S1–S266.
12.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003;289:2560–2572.
13.
Sabbagh M, Rick W, Schneider S: A kinetic method for the direct determination of creatinine in serum with 3,5-dinitrobenzoic acid without deproteinization. J Clin Chem Clin Biochem 1988;26:15–24.
14.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32:S62–S67.
15.
Adult Treatment Panel III: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel of Detection: evaluation and treatment of high blood cholesterol in adults. Final report. Circulation 2002;106:3143–3421.
16.
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089–2100.
17.
Vassalotti JA, Stevens LA, Levey AS: Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50:169–180.
18.
Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, King K, Klag MJ, Molony DA, Flack JM: Early detection of kidney disease in community settings: the kidney early evaluation program (KEEP). Am J Kidney Dis 2003;42:22–35.
19.
Freedman BI, Soucie JM, McClellan WM: Family History of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 1997;8:1942–1945.
20.
Freedman BI, Volkova NV, Satko SG, Krisher J, Jurkovitz C, Soucie JM, McClellan WM: Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol 2005;25:529–535.
21.
Goldfarb-Rumyantzev, Cheung KA, Habib AN, Wang BJ, Lin S, Baird BC, Naiman N, Cannon-Albright L: A population-based assessment of the familial component of chronic kidney disease mortality. Am J Nephrol 2006;26:142–148.
22.
Jurkovitz C, Franch H, Shoham D, Bellenger J, McClellan W: Family members of patients treated for ESRD have high rates of undetected kidney disease. Am J Kidney Dis 2002;40:1173–1178.
23.
Tang W, Hong Y, Province MA, Rich SS, Hopkins PN, Arnett DK, Pankow JS, Miller MB, Eckfeldt JH: Familial clustering for features of the metabolic syndrome. Diabetes Care 2006;29:631–636.
24.
Sedor JR, Schelling JR: Association of metabolic syndrome in nondiabetic patients with increased risk for chronic kidney disease: the fat lady sings. J Am Soc Nephrol 2005;16:1880–1882.
25.
Kambham N, Markowitz SG, Valeri MA, Lin J, D’Agati VD: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498–1509.
26.
Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O: Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006;17:1695–1702.
27.
Domrongkitchaiporn S, Sritara P, Kitiyakara C, Stitchantrakul W, Krittaphol V, Lolekha P, Cheepudomwit S, Yipintsoi T: Risk factors for development of decreased kidney function in a Southeast Asian population: a 12-year cohort study. J Am Soc Nephrol 2005;16:791–799.
28.
Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE: Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000;133:585–591.
29.
Halimi JM, Giraudeau B, Vol S, Caces E, Nivet H, Lebranchu Y, Tichet J: Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000;58:1285–1292.
30.
Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG: Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000;57:2072–2079.
31.
Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003;14:2084–2091.
32.
Ahmed I, John GT, Kirubakaran MG, Jacob CK, Muliyil J: Prevalence of proteinuria in rural adult population in Tamil Nadu. Indian J Med Res 2006;124:185–188.
33.
Mani MK: Prevention of chronic renal failure at the community level. Kidney Int 2003;63(suppl 83):S86–S89.
34.
Mani MK: Experience with a program for prevention of chronic renal failure in India. Kidney Int 2005;67(suppl 94):S75–S78.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.